Allergy Therapeutics (OTCMKTS:AGYTF) vs. Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Review

Allergy Therapeutics (OTCMKTS:AGYTF) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Allergy Therapeutics and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allergy Therapeutics	N/A	N/A	N/A
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%

Volatility & Risk

Allergy Therapeutics has a beta of 12.76, indicating that its share price is 1,176% more volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Earnings and Valuation

This table compares Allergy Therapeutics and Shuttle Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allergy Therapeutics	$71.22 million	1.06	-$51.94 million	N/A	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($11.84)	-0.06

Shuttle Pharmaceuticals has lower revenue, but higher earnings than Allergy Therapeutics.

Institutional and Insider Ownership

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Allergy Therapeutics and Shuttle Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allergy Therapeutics	0	0	0	0	0.00
Shuttle Pharmaceuticals	1	0	0	0	1.00

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.